Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI Summary - About
Imunon Inc(IMNN)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for IMNN
09/23/2026: IMNN (1-star) is currently NOT-A-BUY. Pass it for now.
Imunon Inc is a clinical-stage biotechnology company developing DNA-based immunotherapies for cancer and infectious diseases. Its primary value proposition rests on the proprietary TheraPlas platform, which aims to provide effective treatments with improved safety profiles. The company's main strength is its specialized R&D focus, while its most significant risk involves the high uncertainty of clinical trial success and its dependence on external capital. As a pre-revenue firm with no commercial products, the stock is speculative and best suited for investors with a very high risk tolerance. Future developments to monitor include upcoming clinical trial data and potential strategic partnerships with larger pharmaceutical entities.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Weak fit | The company is in an early, high-risk stage without proven commercial growth. |
| Momentum investor | Weak fit | The stock lacks the sustained upward price action typically required for momentum strategies. |
| Value investor | Weak fit | There are no earnings or cash flows to support traditional value-based valuation models. |
| Dividend investor | Weak fit | The company does not pay dividends and reinvests all capital into R&D. |
| Low-risk investor | Weak fit | Biotechnology R&D poses extreme volatility and binary success-or-failure risks. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Clinical-stage stocks frequently experience sharp price swings based on trial data and financing news. |
| Valuation risk | High | Valuation is speculative and heavily dependent on uncertain future clinical success. |
| Competition risk (Pharma/Biotech) | High | Large incumbents have significantly more resources for drug development and commercialization. |
| Business quality | Medium | The company is an R&D venture without current commercial operations or sustainable cash flow. |
| Dividend income | Low / none | This investment provides zero income to shareholders. |
| Execution risk | High | Clinical trials are complex and often fail to meet endpoints required for regulatory approval. |
Price Behavior
Steep Decline
The stock price has dropped sharply with strong downward pressure.
Moderately Choppy
The stock has experienced noticeable price swings while retaining some directional structure.
Analysis of Past Performance
Type Stock | Historic Profit -73.94% | Avg. Invested days 10 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/23/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 8.25M USD | Price to earnings Ratio - | 1Y Target Price 17 |
Price to earnings Ratio - | 1Y Target Price 17 | ||
Volume (30-day avg) 109.8K shares | Beta 1.98 | 52 Weeks Range 1.33 - 5.55 | Updated Date 09/23/2026 |
52 Weeks Range 1.33 - 5.55 | Updated Date 09/23/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.92 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Clinical Stage Research | Ongoing clinical trials for IMNN-001 and potential development of PLACCINE. | The company currently burns cash to conduct science and has no product sales. |
Valuation
Trailing PE - | Forward PE 16.78 | Enterprise Value 9.45M | Price to Sales(TTM) 17.94 |
Enterprise Value 9.45M | Price to Sales(TTM) 17.94 | ||
Enterprise Value to Revenue 4 | Enterprise Value to EBITDA 0.91 | Shares Outstanding 5.61M | Shares Floating 5.28M |
Shares Outstanding 5.61M | Shares Floating 5.28M | ||
Percent Insiders 5.73 | Percent Institutions 5.68 |
Upturn AI Summary
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
About Imunon Inc
Exchange NASDAQ | Headquarters Lawrenceville, NJ, United States | ||
IPO Launch date 1999-03-01 | President, CEO & Director Dr. Stacy R. Lindborg Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 20 | Website https://imunon.com |
Full time employees 20 | Website https://imunon.com | ||
Imunon, Inc., a clinical-stage biotechnology company, focuses on developing immunotherapies and vaccines in the United States. The company's lead clinical program is IMNN-001, a DNA-based immunotherapy that is in a Phase 3 clinical trial for the localized treatment of advanced ovarian cancer, as well as in the IND-enabling phase for colorectal and pancreatic cancers, and in the discovery phase for glioblastoma. It is also developing IMNN-101, a COVID-19 booster vaccine that has completed a Phase 1 clinical trial. In addition, the company develops non-viral DNA technology across modalities, such as TheraPlas for the coding of proteins and cytokines in the treatment of solid tumors; and PlaCCine for the coding of viral antigens that can elicit a strong immunological response. The company was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in September 2022. Imunon, Inc. was incorporated in 1982 and is headquartered in Lawrenceville, New Jersey.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.